Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML / 전남의대학술지
Chonnam Medical Journal
;
: 80-84, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-154041
ABSTRACT
The sensitization of leukemia cells with hematopoietic growth factors can enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). Therefore, the current trial attempted to evaluate the efficacy of granulocyte colony-stimulating factor (G-CSF) priming in remission induction chemotherapy with an intensified dose of Ara-C for newly diagnosed AML. Patients with newly diagnosed AML were randomly assigned to receive idarubicin (12 mg/m2/24 hr, days 1-3) plus Ara-C (500 mg/m2/12 hr, days 4-8) with G-CSF (250 microg/m2/d, days 3-7) (IAG group) or standard idarubicin (12 mg/m2/24 hr, days 1-3) plus Ara-C (100 mg/m2/12 hr, days 1-7) without G-CSF (IA group). There were no significant differences in sex, age, subtype, or cytogenetic risk between the two groups. Complete remission was achieved in 15 patients (88.2%) from the IAG group and in 14 patients (82.4%) from the IA group (p=0.31). The median time to complete remission was 26 vs. 31 days (p=0.779) for the IA and IAG groups, respectively. The median time to neutrophil recovery (>1x10(9)/L) and platelet recovery (>20x10(9)/L) did not differ significantly between the two groups (26 vs. 26 days, p=0.338; 21 vs. 16 days, p=0.190, respectively). After a median follow-up of 682 days, the 3-year overall survival rate for the IA group was 64.7%, whereas that for the IAG group was 45.6% (p=0.984). No improved clinical outcomes were observed for the AML patients subjected to intensified remission induction with G-CSF priming when compared with standard induction chemotherapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Plaquetas
/
Inducción de Remisión
/
Idarrubicina
/
Leucemia Mieloide Aguda
/
Leucemia
/
Distribución Aleatoria
/
Tasa de Supervivencia
/
Estudios Prospectivos
/
Estudios de Seguimiento
/
Factor Estimulante de Colonias de Granulocitos
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Humanos
Idioma:
Inglés
Revista:
Chonnam Medical Journal
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS